

## Recombinant SARS-Cov-2 Spike S1 protein (69/70 deletion, 144Y deletion, N501Y, A570D, D614G, P618H), His (HEK293)

Catalog Number: bs-41456P

Concentration: >0.5 mg/ml

AA Seq: 14-685/1273

Predicted MW: 78.6

Detected MW: 110-130 kDa

Tags: His

Activity: Yes

Endotoxin: Not analyzed

Purity: >95% as determined by SDS-PAGE

Purification: AC


Form: Lyophilized or Liquid

Storage: 10mM TBS (pH7.4).

Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.


**Background:** The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

### VALIDATION IMAGES



Measured by its binding ability in a functional ELISA.

Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2µg/ml (100ul/Well) can bind SARS-CoV-2 Spike S1 (69/70 deletion, 144Y deletion, N501Y, A570D, D614G, P618H), His Tag (Cat: bs-41456P), the EC50 is 131.51ng/ml.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.